Which method answers which question?
| Document or method | Information provided | What it does not establish alone |
|---|---|---|
| CoA / certificate of analysis | Reported test results for a particular batch | That every batch has received the same detailed characterisation |
| Chromatography such as HPLC | Active identity, amount or related impurities with a suitable method | Presence of liposomal structure |
| DLS | Hydrodynamic size and distribution information under the test conditions | Microscopic carrier morphology |
| TEM / suitable microscopy | Images informing structure and morphology in the prepared sample | Human absorption or clinical outcomes |
| Encapsulation assessment | Method-dependent distinction between free and carrier-associated active | An automatic finished-product shelf life |
Source: FDA (2018) — Liposome Drug Products; analytical assessment framework; NCI — NCL characterisation methods; NIST SP 1200-6 (2015) — Particle size measurement by DLS
Read size data with the test conditions
DLS reports a hydrodynamic measurement. Sample preparation, measurement medium, temperature and analysis approach influence interpretation. A microscopy-derived size should not necessarily be expected to match the DLS result exactly.
PDI provides information about distribution breadth. Rather than applying one PDI limit to every active and product form, review the method and the manufacturer’s justified specification. A useful report identifies the sample and how it was measured, not merely the final number.
Source: NIST SP 1200-6 (2015) — Particle size measurement by DLS; NCI — NCL characterisation methods
Active content and encapsulation are different measurements
Total active content is different from the amount reported as incorporated in the carrier. Encapsulation data should explain the separation method, calculation basis and sample-preparation conditions. Structural disruption during testing or incomplete separation can affect the result.
The basis of the active amount also needs clarification: total ingredient weight, dry matter, a specified compound or elemental content. The serving calculation should use that definition consistently.
Source: FDA (2018) — Liposome Drug Products; analytical assessment framework
Connect batch documentation with the technical file
When assessing a sample or quotation with Biontera, matching document identity is as important as matching the product name and code. It helps preserve traceability between the dossier reviewed by formulation teams and the ingredient ordered by procurement.
- Manufacturer, product code, batch number and document date.
- Test method, units, acceptance range and reported result.
- Whether characterisation relates to the supplied batch or a representative development batch.
- Microbiological quality and other product-appropriate quality parameters.
- Storage conditions and retest or expiry date.
How the references are used
The FDA guidance for liposomal drug products and NCI methods are used here to explain analytical assessment topics. They do not establish FDA approval of Biontera ingredients or a universal testing list for all food supplements. The appropriate assessment is determined from the product and its technical dossier.
Source: FDA (2018) — Liposome Drug Products; analytical assessment framework; NCI — NCL characterisation methods